Claims
- 1. A medical device manufactured from a composition comprising:an aromatic high refractive index monomer; a non-ultraviolet light absorbing hydrophilic monomer present in said composition in an amount greater than that of said high refractive index monomer; a crosslinker; and an initiator to form a hydrogel composition having a fully hydrated water content of approximately 5 to 30 percent by weight and a fully hydrated refractive index of approximately 1.45 or greater.
- 2. The medical device of claim 1 wherein said composition includes a hydrophobic ultraviolet light absorbing material selected from the group consisting of beta-(4-benzotriazoyl-3-hydroxyphenoxy)ethyl acrylate, 4-(2-acryloxyethoxy)-2-hydroxybenzophenone, 4-methacryloxy-2-hydroxybenzophenone, 2-(2′-methacryloxy-5′-methylphenyl)benzotriazole, 2-(2′-hydroxy-5′-methacryoxyethylphenyl)-2H-benzotriazole, 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacyloyloxypropyl)phenyl]-5-chlorobenzotriazole, 2-(3′-tert-Butyl-5′-(3-dimethylvinylsilylpropoxy)-2′-hydroxyphenyl]-5-methoxybenzothiazole, 2-(3′-Allyl-2′-hydroxy-5′-methylphenyl)benzotriazole, 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacryloyloxypropoxy)]phenyl]-5-methoxybenzotriazole and 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacryloyloxypropoxy)phenyl]-5-chlorobenzotriazole.
- 3. The medical device of claim 1 wherein said composition includes beta-(4-benzotriazoyl-3-hydroxyphenoxy)-ethyl acrylate as an ultraviolet light absorbing material.
- 4. The medical device of claim 1 wherein said initiator is selected from the group consisting of azobis(isobutyronitrile), 2,2′-azobis(2,4-dimethylvaleronitrile), 2,2′azobis(methylbutyronitrile), 1,1′-azobis(cyanocyclohexane), di-t-butyl peroxide, dicumyl peroxide, t-butylcumyl peroxide, 2,5-dimethyl-2,5-bis(2-ethylhexanoylperoxy)hexane, t-butylperoxyneodecanote, t-butyl peroxy 2-ethylhexanoate, d i(4-t-butyl cyclohexyl) peroxydicarbonate, t-butyl peroxypivalate, decanoyl peroxide, lauroyl peroxide, benzoyl peroxide, 2,4-pentanedione peroxide, di(n-propyl)peroxydicarbonate, t-amyl peroxyneodecanoate and t-butyl peroxyacetate.
- 5. The medical device of claim 1 wherein said initiator is azobis(isobutyronitrile).
- 6. The medical device of claim 1 wherein said crosslinker is selected from the group consisting of ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate and poly(ethylene glycol) dimethacrylate.
- 7. The medical device of claim 1 wherein said crosslinker is ethylene glycol dimethacrylate.
- 8. The medical device of claim 1 wherein said hydrophilic monomer is a monomer represented by the formula wherein R1 is selected from the group consisting of hydrogen and C1-6 alkyl, and R2 is selected from the group consisting of hydrogen, an alkali metal, an alkaline earth metal, C1-6 hydroxyalkyl, C4-12 hydroxyalkoxyalkyl, C4-12 hydroxydialkoxyalkyl, C2-12 alkoxyalkyl, C3-12 polyalkoxyalkyl, C3-15 polyalkoxyhydroxyalkyl and C2-12 dihydroxyalkyl.
- 9. The medical device of claim 1 wherein said hydrophilic monomer is selected from the group consisting of 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, sodium methacrylate, glycerol methacrylate, hydroxypropyl methacrylate, and hydroxybutyl methacrylate.
- 10. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate.
- 11. The medical device of claim 1 wherein said high refractive index monomer is a monomer represented by one of the formulas wherein R3 is selected from the group consisting of hydrogen and C1-6 alkyl, R4 is selected from the group consisting of C6-25 aryl, C6-25 hydroxyaryl, C6-25 aryloxyaryl, C12-25 polyhydroxyaryl, C12-35 polyaryl, C6-15 arylalkyl, C12-35 polyarylalkyl, C6-15 alkoxyaryl, C6-15 aryl halides, C6-15 aryloxyalkyl, C1-7 alkyl halides, C6-15 arylthioalkyl, C6-15 aryloxyalkyl halides and C6-15 aryloxyalkoxyalkyl, and R5 is selected from the group consisting of hydrogen, C1-3 alkyl and C6-15 alkylaryl.
- 12. The medical device of claim 1 wherein said high refractive index monomer is selected from the group consisting of phenyl acrylate, phenyl methacrylate, benzyl acrylate, benzyl methacrylate, 2-phenylethyl acrylate, 2-phenylethyl methacrylate, 2-phenoxyethyl acrylate, 2-phenoxyethyl methacrylate, phenylthioethyl acrylate, phenylthioethyl methacrylate, 2,4,6-tribromophenyl acrylate, 2,4,6-tribromophenyl methacrylate, pentabromophenyl acrylate, pentabromophenyl methacrylate, pentachlorophenyl acrylate, pentachlorophenyl methacrylate, 2,3-dibromopropyl acrylate, 2,3-dibromopropyl methacrylate, 2-naphthyl acrylate, 2-naphthyl methacrylate, 4-methoxybenzyl acrylate, 4-methoxybenzyl methacrylate, 2-benzyloxyethyl acrylate, 2-benzyloxyethyl methacrylate, 4-chlorophenoxyethyl acrylate, 4-chlorophenoxyethyl methacrylate, 2-phenoxyethoxyethyl acrylate, 2-phenoxyethoxyethyl methacrylate, N-phenyl acrylamide, N-phenyl methacrylamide, N-benzyl acrylamide, N-benzyl methacrylamide, N,N-dibenzyl acrylamide, N,N-dibenzyl methacrylamide, N-diphenylmethyl acrylamide N-(4-methylphenyl)methyl acrylamide, N-1-naphthyl acrylamide, N-4-nitrophenyl acrylamide, N-(2-phenylethyl)acrylamide, N-triphenylmethyl acrylamide, N-(4-hydroxyphenyl)acrylamide, N,N-methylphenyl acrylamide, N,N-phenyl phenylethyl acrylamide, N-diphenylmethyl methacrylamide, N-(4-methyl phenyl)methyl methacrylamide, N-1-naphthyl methacrylamide, N-4-nitrophenyl methacrylamide, N-(2-phenylethyl)methacrylamide, N-triphenylmethyl methacrylamide, N-(4-hydroxyphenyl)methacrylamide, N,N-methylphenyl methacrylamide, N,N′-phenyl phenylethyl methacrylamide, N-vinylcarbazole, 4-vinylpyridine, 2-vinylpyridine, styrene, 2-chlorostyrene, 3-chlorostyrene, 4-chlorostyrene, 2-bromostyrene, 3-bromostyrene, 4-bromostyrene, 2,6-dichlorostyrene, 2-iodostyrene, 3-lodostyrene, 4-iodostyrene, pentabromostyrene, 4-phenylstyrene, 1-vinylnaphthalene, 2-vinylnaphthalene, 9-vinylanthracene and 4-phenoxystyrene.
- 13. The medical device of claim 1 wherein said high refractive index monomer and said hydrophilic monomer comprise at least about 70 percent by weight of said composition.
- 14. The medical device of claim 1 wherein said high refractive index monomer and said hydrophilic monomer comprise approximately 75 percent by weight of said composition.
- 15. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is phenyl methacrylate.
- 16. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is benzyl acrylate.
- 17. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is benzyl methacrylate.
- 18. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is 2-phenylethyl acrylate.
- 19. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is 2-phenylethyl methacrylate.
- 20. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is 2-phenoxyethyl acrylate.
- 21. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is 2-phenoxyethyl methacrylate.
- 22. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is N-benzyl methacrylamide.
- 23. The medical device of claim 1 wherein said hydrophilic monomer is 2-hydroxyethyl methacrylate and said high refractive index monomer is N-vinylcarbazole.
Parent Case Info
This application is a divisional application of prior application Ser. No. 09/209,552 filed Dec. 11, 1998 now U.S. Pat. No. 6,329,485.
US Referenced Citations (26)
Foreign Referenced Citations (5)
| Number |
Date |
Country |
| 0 869 138 |
Oct 1998 |
EP |
| 2 757 065 |
Jun 1998 |
FR |
| WO 9407686 |
Apr 1994 |
WO |
| WO 96 40303 |
Dec 1996 |
WO |
| WO 97 24382 |
Jul 1997 |
WO |
Non-Patent Literature Citations (1)
| Entry |
| Patent Abstracts of Japan (vol. 1999, No. 08), Publication No. 11056999, Publication Date: Feb. 03, 1999, Title: Soft Intra-Eye Lens Material. |